Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (181-190 of 303) with videos related to

Pageof 31
Sort By:
Journal of Gastroenterology and Hepatology|February 20, 2009
Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunctionZeid Kayali, Jason Herring, Pedro Baron, et al.
Cancer Research|October 1, 2009
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitroAndrea E Wahner Hendrickson, Paul Haluska, Paula A Schneider, et al.
Arthritis Care & Research|April 26, 2016
Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of LupusAngela George, Andrew Wong-Pack, Christine A Peschken, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based SurveyEun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.
The Journal of Biological Chemistry|August 19, 2007
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitizationXue Wei Meng, Sun-Hee Lee, Haiming Dai, et al.
Arthritis and Rheumatism|November 1, 2008
Assessment of reproductive history in systemic sclerosisSasha Bernatsky, Marie Hudson, Janet Pope, et al.
Journal of Cellular Biochemistry|May 23, 2014
Osteoblasts protect AML cells from SDF-1-induced apoptosisKimberly N Kremer, Amel Dudakovic, Meghan E McGee-Lawrence, et al.
The Journal of Rheumatology|November 17, 2010
Medication use in systemic lupus erythematosusSasha Bernatsky, Christine Peschken, Paul R Fortin, et al.
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Pageof 31

Showing results (181-190 of 303) with videos related to

Sort By:
Pageof 31
Journal of Gastroenterology and Hepatology|February 20, 2009
Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunctionZeid Kayali, Jason Herring, Pedro Baron, et al.
Cancer Research|October 1, 2009
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitroAndrea E Wahner Hendrickson, Paul Haluska, Paula A Schneider, et al.
Arthritis Care & Research|April 26, 2016
Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of LupusAngela George, Andrew Wong-Pack, Christine A Peschken, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 14, 2015
Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based SurveyEun-Ju Lee, B Douglas Smith, Jessica W Merrey, et al.
Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.
The Journal of Biological Chemistry|August 19, 2007
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitizationXue Wei Meng, Sun-Hee Lee, Haiming Dai, et al.
Arthritis and Rheumatism|November 1, 2008
Assessment of reproductive history in systemic sclerosisSasha Bernatsky, Marie Hudson, Janet Pope, et al.
Journal of Cellular Biochemistry|May 23, 2014
Osteoblasts protect AML cells from SDF-1-induced apoptosisKimberly N Kremer, Amel Dudakovic, Meghan E McGee-Lawrence, et al.
The Journal of Rheumatology|November 17, 2010
Medication use in systemic lupus erythematosusSasha Bernatsky, Christine Peschken, Paul R Fortin, et al.
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Pageof 31